Skip to main content

Simple Voltage Criteria for LVH on ECG

Lvh findings on ecg

Cornell Duration Product in ECG: Detailed, Practical Guide for Clinicians

Left ventricular hypertrophy (LVH) is a key marker of chronic pressure overload and adverse cardiovascular outcomes. Among ECG-based criteria, the Cornell Duration Product (CDP) improves diagnostic accuracy by combining voltage with QRS duration, making it superior to voltage-only criteria in many clinical settings.


Concept and Rationale

Traditional ECG criteria for LVH rely mainly on QRS voltage, which is influenced by body habitus, age, and sex. The Cornell Duration Product incorporates QRS duration, reflecting both myocardial mass and conduction time. This integration enhances sensitivity for detecting true anatomical LVH.


What Is the Cornell Duration Product

The Cornell Duration Product is calculated by multiplying the Cornell voltage by the QRS duration.


Cornell voltage is defined as:

• S wave amplitude in lead V3

• Plus R wave amplitude in lead aVL


Cornell Duration Product = [S(V3) + R(aVL)] × QRS duration (ms)


All voltages are measured in millimeters (mm), and QRS duration is measured in milliseconds (ms), giving a final unit of mm·ms.


Gender Adjustment

Because women typically have lower ECG voltages, a correction is applied:

• Men: use measured S(V3) + R(aVL)

• Women: add 6 mm to the voltage sum before multiplying by QRS duration


Diagnostic Cut-Off

A Cornell Duration Product value:

• > 2440 mm·ms is diagnostic of left ventricular hypertrophy


This cut-off is validated across multiple populations and correlates well with echocardiographic LV mass.


How to Measure Step-by-Step


1. Identify lead V3 and measure the depth of the S wave in millimeters



2. Identify lead aVL and measure the height of the R wave in millimeters



3. Add the two values (apply +6 mm if the patient is female)



4. Measure QRS duration from the earliest onset to the latest offset of the QRS complex in any lead



5. Multiply voltage sum by QRS duration




Clinical Significance

The Cornell Duration Product has several advantages:

• Higher sensitivity than Sokolow–Lyon criteria

• Better correlation with echocardiographic LV mass

• Strong association with cardiovascular morbidity and mortality

• Useful in hypertension, aortic stenosis, and chronic kidney disease


Studies have shown that regression of LVH assessed by Cornell Duration Product during antihypertensive therapy is associated with improved cardiovascular outcomes.


Comparison With Other ECG Criteria

Sokolow–Lyon Criterion

• Based purely on voltage

• High specificity but low sensitivity

• Less reliable in obese and elderly patients


Cornell Voltage Alone

• More sensitive than Sokolow–Lyon

• Still limited by ignoring QRS duration


Cornell Duration Product

• Incorporates both voltage and conduction time

• Best ECG-based predictor of anatomical LVH

• Preferred in research and risk stratification


Limitations

Despite its advantages, Cornell Duration Product has limitations:

• Reduced accuracy in bundle branch block or paced rhythms

• Influenced by myocardial fibrosis and conduction abnormalities

• ECG cannot replace echocardiography or cardiac MRI for definitive LV mass assessment


Exam and Clinical Pearl

When ECG voltage is borderline but QRS duration is prolonged, the Cornell Duration Product can unmask clinically significant LVH that would otherwise be missed.


One-Line Formula for Quick Recall

Cornell Duration Product = [S(V3) + R(aVL)] × QRS duration


This simple calculation adds significant diagnostic value to routine ECG interpretation and should be part of every clinician’s LVH assessment toolkit.



Comments

Popular posts from this blog

STEMI ECG Criteria and Universal Definition of MI

  STEMI ECG Criteria and the Universal Definition of Myocardial Infarction: A Complete Guide for Clinicians Early and accurate diagnosis of acute myocardial infarction (AMI) remains the cornerstone of reducing morbidity and mortality in patients presenting with chest pain. Among all forms of acute coronary syndromes (ACS), ST-elevation myocardial infarction (STEMI) represents the most time-sensitive emergency, requiring immediate reperfusion therapy. This article provides a clinically relevant summary of the STEMI ECG criteria and the Universal Definition of Myocardial Infarction (UDMI), based on the latest consensus guidelines from the ESC, ACC, AHA, and WHF. --- 1. Understanding STEMI: Why Accurate ECG Interpretation Matters A 12-lead ECG remains the first and most critical diagnostic test when evaluating suspected myocardial infarction. STEMI is identified when there is evidence of acute coronary artery occlusion, producing transmural ischemia and characteristic ST-segment eleva...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.